The HERMES (Harmonizing Endovascular Revascularization in Minor Ischemic Stroke) collaboration represents a pivotal moment in the evolution of acute ischemic stroke (AIS) treatment. This landmark initiative, encompassing five pivotal trials, has significantly reshaped clinical practice guidelines and improved patient outcomes. Its findings, readily accessible through PubMed searches, have redefined our understanding of endovascular thrombectomy (EVT) efficacy, patient selection criteria, and the role of novel therapeutic agents in managing AIS. This article will delve into the key contributions of the HERMES trials, exploring their impact on various aspects of stroke intervention.
Endovascular Thrombectomy After Large Vessel Occlusion (LVO): A Paradigm Shift
Before the HERMES trials, the landscape of AIS treatment was significantly less defined. While the benefits of EVT for patients with LVO were emerging, the evidence base was fragmented and lacked the robust data needed to solidify its widespread adoption. The HERMES collaboration addressed this critical gap by contributing crucial data on the efficacy and safety of EVT in a diverse range of patients with LVO. PubMed searches readily reveal numerous publications dissecting the results of these trials, highlighting the significant improvement in functional outcomes—measured by scales like the modified Rankin Scale (mRS)—achieved through timely EVT. The trials demonstrated a clear benefit in terms of reduced disability and mortality compared to medical management alone, solidifying EVT's position as the gold standard treatment for select patients with LVO. This shift was not without its nuances, however, as the HERMES data also helped refine the selection criteria for optimal candidates, leading to a more targeted and effective application of this life-saving procedure.
HERMES: Messenger for Stroke Interventional Treatment
The name HERMES, drawing inspiration from the Greek messenger god, aptly reflects the trials' role in conveying crucial information to the global neurology community. The HERMES collaboration served as a powerful messenger, disseminating critical data that influenced clinical practice guidelines worldwide. PubMed provides access to a wealth of literature analyzing the implications of the HERMES findings for various aspects of stroke care, including patient selection, procedural techniques, and post-treatment rehabilitation strategies. The trials' impact extends beyond the immediate clinical setting, influencing research agendas and prompting further investigation into novel therapeutic approaches and technological advancements in EVT. The collective body of work resulting from HERMES has reshaped the way stroke is treated globally, leading to improved patient care and outcomes.
Endovascular Treatment Effect Diminishes With Increasing Time to Treatment: A Critical Finding
One of the most significant contributions of the HERMES trials is the clear demonstration of the time-dependent nature of EVT efficacy. PubMed searches reveal numerous analyses emphasizing the importance of rapid reperfusion in achieving optimal outcomes. The data consistently showed a diminishing benefit of EVT with increasing time from symptom onset to treatment. This finding underscores the critical importance of streamlined prehospital care, rapid diagnosis, and efficient transfer to centers equipped to perform EVT. The HERMES trials have highlighted the need for robust stroke systems of care, emphasizing the crucial role of prehospital stroke recognition, rapid emergency department assessment, and efficient transfer pathways to specialized stroke centers. These findings have driven initiatives aimed at improving the speed and efficiency of AIS care, leading to the development and implementation of various pre-hospital and in-hospital strategies to reduce door-to-needle times.
current url：https://btecpw.ec581.com/products/hermes-stroke-pubmed-42266